Acrotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACROTECH
ACROTECH has seven approved drugs.
There are twelve US patents protecting ACROTECH drugs.
There are two hundred and five patent family members on ACROTECH drugs in thirty-five countries and eight supplementary protection certificates in seven countries.
Summary for Acrotech
| International Patents: | 205 |
| US Patents: | 12 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 7 |
Drugs and US Patents for Acrotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrotech Biopharma | ADQUEY | difamilast | OINTMENT;TOPICAL | 219474-001 | Feb 12, 2026 | RX | Yes | Yes | 10,588,893 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 10,864,183 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 9,493,582 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 9,200,088 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Acrotech Biopharma | ADQUEY | difamilast | OINTMENT;TOPICAL | 219474-001 | Feb 12, 2026 | RX | Yes | Yes | RE46792 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Acrotech Biopharma | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | 6,888,027 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-002 | Oct 19, 2018 | DISCN | Yes | No | 11,541,012 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acrotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acrotech Biopharma | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-002 | Sep 24, 2009 | 8,299,078 | ⤷ Start Trial |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 7,247,316 | ⤷ Start Trial |
| Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | 6,500,829 | ⤷ Start Trial |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,814,335 | ⤷ Start Trial |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,543,152 | ⤷ Start Trial |
| Acrotech Biopharma | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-002 | Sep 24, 2009 | 6,028,071 | ⤷ Start Trial |
| Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 6,723,338 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACROTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 500 mg/vial | ➤ Subscribe | 2018-07-03 |
| ➤ Subscribe | Injection | 10 mg/mL, 17.5 mL vial and 25 mL vial | ➤ Subscribe | 2011-10-26 |
| ➤ Subscribe | Injection | 20 mg/mL and 40 mg/2 mL | ➤ Subscribe | 2013-09-24 |
| ➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2017-09-08 |
| ➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2013-12-19 |
International Patents for Acrotech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010138920 | ⤷ Start Trial |
| South Africa | 201904909 | ⤷ Start Trial |
| European Patent Office | 2292593 | ⤷ Start Trial |
| Japan | 6517725 | ⤷ Start Trial |
| Singapore | 11201805364T | ⤷ Start Trial |
| Brazil | 112015008954 | ⤷ Start Trial |
| China | 108473448 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acrotech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2701720 | 122023000007 | Germany | ⤷ Start Trial | PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817 |
| 2701720 | 3/2023 | Austria | ⤷ Start Trial | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
| 2701720 | 23C1000 | France | ⤷ Start Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
| 2701720 | CR 2022 00054 | Denmark | ⤷ Start Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
| 2701720 | 202240050 | Slovenia | ⤷ Start Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1669/001; DATE OF NATIONAL AUTHORISATION: 20220817; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2701720 | SPC/GB23/004 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818 |
| 2701720 | CA 2022 00054 | Denmark | ⤷ Start Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
